Education and Training
Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases
This clinical trial studies the use of sodium fluorine-18 (18F-NaF) plus fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/ whole body magnetic resonance imaging (WBMRI) to detect skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate cancer.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Gadopentetate dimeglumine
- drug: Gadofosveset
- drug: Gadobutrol
- procedure: Bone scan
- procedure: Positron Emission Tomography (PET) scan
- drug: 18F-Fludeoxyglucose (18F-FDG)
- procedure: Computed Tomography (CT) scan
- drug: 18F-Sodium Fluoride (18F-NaF)
- procedure: Whole Body Magnetic Resonance Imaging (WB-MRI) scan
- drug: 99mTc-methyl diphosphonate
Eligibility
All patients were enrolled after receiving a regular medical care bone scan using the
radiolabel 99mTc-methyl diphosphonate (t99-MDP).
INCLUSION CRITERIA
- ≥ 18 years old at the time of the drug administration
- ≥ Stage 3 breast cancer OR ≥ stage 2 prostate cancer OR prostate-specific antigen
(PSA) > 10 micrograms/L OR recurrent breast or prostate cancer
- Capable of complying with study procedures
- Able to remain still for duration of imaging procedure (about one hour)
- Written informed consent
EXCLUSION CRITERIA
- Pregnant or nursing
- Metallic implants that contraindicate MRI
- Renal function impairment that contraindicates MRI
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061
Not Recruiting